Article
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients.
Pharmacogenetics and genomics - 1 Jul 2024
Sabirova Zarina, Mahnoor Shazia, Lasfar Dina, Gagné Vincent, Théorêt Yves, Leclerc Jean Marie, Laverdière Caroline, Sinnett Daniel, Tran Thai-Hoa, Krajinovic Maja
Abstract excerpt
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. 6-Mercaptopurine (6-MP) is a key component of ALL treatment. Its use, however, is also associated with adverse drug reactions, particularly myelosuppression. Thiopurine S-methyltransferase (TPMT) and, more recently, Nudix hydrolase 15 (NUDT15) deficiency, due to no-function variants in their respective genes, are well known for their role...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
